New pill tested to control rare blood cancers
NCT ID NCT05153343
Summary
This early-stage study tested a new oral drug called flonoltinib in adults with myeloproliferative neoplasms (MPNs), a group of rare bone marrow cancers. The main goals were to check the drug's safety, find the highest tolerable dose, and see how the body processes it. Researchers enrolled 31 patients with conditions like myelofibrosis, polycythemia vera, or essential thrombocythemia to gather this initial data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM (MPN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.